neuroblastoma | GenomeWeb

neuroblastoma

The work offers a proof of concept for the notion that dynamic models of signaling could serve as more effective biomarkers than discrete molecular markers.

This Week in Nature

In Nature this week: genetic rearrangements in high-risk neuroblastoma, and more.

Using funds from the California precision medicine initiative, the group will use its bioinformatics expertise to match patients to treatments in pediatric clinical trials.

In Genome Biology this week: intra-tumor heterogeneity assessed with single-cell RNA sequencing, common epigenetic alterations in tumors, and more.

Researchers found alterations that activate the RAS-MAPK pathway in 18 of 23 relapse neuroblastoma tumors tested.

Entrectinib is Ignyta's lead product that the biotech is investigating in patients with tumors characterized by TrkA, TrkB, TrkC, ROS1, and ALK markers.

NEW YORK (Genomeweb) — A study comprehensively analyzing the genomes of more than 1,500 neuroblastoma cases has better determined the prognostic significance of ALK mutations and other alterations in neuroblastoma, and has biochemically investigated many of these variants to determine which ones

NEW YORK (GenomeWeb News) — The New York Genome Center and The Sohn Conference Foundation said today that they have launched The Sohn Collaborative for Pediatric Cancer Research.

Researchers from several European institutions have used a clinical trial of children with stage IV neuroblastoma to test prospectively whether varying levels of several mRNA markers could stratify patients according to their outcomes.

NEW YORK (GenomeWeb News) – A study in Nature Genetics suggests alterations to two chromatin-remodeling genes — ARID1A and ARID1B — are linked to particularly poor neuroblastoma outcomes.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.